Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

Research Article

Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis

Online download statistics by month:

Online download statistics by month: December 2019 to March 2024

	Abstract	Full	Pdf
Dec 2019	1	1	0
Jan 2020	7	7	0
Feb 2020	8	8	1
Mar 2020	30	30	3
Apr 2020	14	14	0
May 2020	34	34	4
Jun 2020	15	15	4
Jul 2020	19	19	2
Aug 2020	16	16	4
Sep 2020	32	32	10
Oct 2020	27	27	2
Nov 2020	26	25	16
Dec 2020	14	14	4
Jan 2021	19	19	1
Feb 2021	16	16	4
Mar 2021	15	15	7
Apr 2021	11	11	4
May 2021	12	12	7
Jun 2021	28	28	8
Jul 2021	13	13	4
Aug 2021	5	5	3
Sep 2021	9	9	6
Oct 2021	26	26	29
Nov 2021	20	20	16
Dec 2021	23	23	8
Jan 2022	39	41	16
Feb 2022	12	13	4
Mar 2022	24	24	8
Apr 2022	13	15	7
May 2022	29	29	10
Jun 2022	36	39	12
Jul 2022	44	54	7
Aug 2022	38	38	5
Sep 2022	48	48	19
Oct 2022	51	58	21
Nov 2022	55	55	12
Dec 2022	21	21	5
Jan 2023	24	24	8
Feb 2023	37	37	7
Mar 2023	20	20	6
Apr 2023	9	10	8
May 2023	3	3	6
Jun 2023	14	14	1
Jul 2023	15	15	12
Aug 2023	9	9	3
Sep 2023	16	16	9
Oct 2023	11	11	6
Nov 2023	16	16	5
Dec 2023	24	26	13
Jan 2024	88	89	31
Feb 2024	10	11	16
Mar 2024	27	27	6
Total	1173	1202	410